SCHEMBL6626327

SCHEMBL6626327

CN=C(C(=O)NC)c1ccccc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.47
TSHR P16473 3/20 0.47
KDM4E B2RXH2 9/20 0.46
HPGD P15428 7/20 0.46
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
GAA P10253 2/20 0.44
MPO P05164 1/20 0.44
HIF1A Q16665 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
HMGB1 P09429 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
CA14 Q9ULX7 1/20 0.44
HSD17B10 Q99714 6/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6626324 1.00 LMNA (0.47) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL2154230 0.86 LMNA (0.47) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL2154229 0.86 LMNA (0.47) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL6626532 0.86 LMNA (0.47) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL3370230 0.81 LMNA (0.51) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL5195934 0.81 LMNA (0.51) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL3370228 0.81 LMNA (0.51) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL6745300 0.77 LMNA (0.53) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL7221642 0.77 LMNA (0.42) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL7221644 0.77 LMNA (0.42) LMNATSHRKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831197-B2 Intermediates, in particular for preparing fungicides BAYER AKTIENGESELLSCHAFT (DE) 2004-12-14 US disclosed
US-20040199014-A1 Method for producing 2-(hydroxyphenyl)-2-(alkoxyimino)-n-methylacetamide derivatives BAYER CROPSCIENCE AG (DE) 2004-10-07 US disclosed
US-20040147782-A1 Methods for producing 2-(2-hydroxyphenyl)-2-(alkoxyimino)-N-methylacetamide derivatives HUBSCH WALTER (DE) 2004-07-29 US disclosed
EP-1417168-A2 METHOD FOR PRODUCING 2-(HYDROXYPHENYL)-2-(ALKOXYIMINO)-N-METHYLACETAMIDE DERIVATIVES Bayer CropScience AG (DE) 2004-05-12 EP disclosed
US-6700017-B1 ALKYLATION, OXIDATION BAYER AKTIENGESELLSCHAFT (DE) 2004-03-02 US disclosed
CN-1399628-A Methods for producing 2-(2-hydroxyphenyl)-2-(alkoxyimino)-n-methylacetamide derivatives BAYER AG (DE) 2003-02-26 CN disclosed
WO-2003014066-A2 METHOD FOR PRODUCING 2-(HYDROXYPHENYL)-2-(ALKOXYIMINO)-N-METHYLACETAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2003-02-20 WO disclosed
EP-1235790-A2 METHODS FOR PRODUCING 2-(2-HYDROXYPHENYL)-2-(ALKOXYIMINO)-N-METHYLACETAMIDE DERIVATIVES Bayer Aktiengesellschaft (DE) 2002-09-04 EP disclosed
WO-2001038294-A2 METHODS FOR PRODUCING 2-(2-HYDROXYPHENYL)-2-(ALKOXYIMINO)-N-METHYLACETAMIDE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2001-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040199014-A1 Method for producing 2-(hydroxyphenyl)-2-(alkoxyimino)-n-methylacetamide derivatives HMOX2, AADAC, HNMT LMNA 788/4885TSHR 4296/4885KDM4E 2496/4885
US-20040147782-A1 Methods for producing 2-(2-hydroxyphenyl)-2-(alkoxyimino)-N-methylacetamide derivatives AADAC, HACL2, AZI2 LMNA 1724/4885TSHR 4354/4885KDM4E 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.